SymBio Pharmaceuticals Limited (TYO:4582)
Japan · Delayed Price · Currency is JPY 87.00
0.00 (0.00%)
Feb 13, 2026, 3:30 PM JST
SymBio Pharmaceuticals Revenue
In the year 2025, SymBio Pharmaceuticals had annual revenue of 1.31B JPY, down -46.67%. SymBio Pharmaceuticals had revenue of 336.84M in the quarter ending December 31, 2025, a decrease of -39.16%.
Revenue
1.31B
Revenue Growth
-46.67%
P/S Ratio
3.96
Revenue / Employee
12.11M
Employees
108
Market Cap
5.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -1.14B | -46.67% |
| Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
| Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
| Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
| Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pharma Foods International | 66.38B |
| Fuso Pharmaceutical Industries,Ltd. | 62.05B |
| Nippon Chemiphar | 32.52B |
| Morishita Jintan | 12.90B |
| Wakamoto Pharmaceutical | 9.43B |
| Taiko Pharmaceutical | 5.94B |
| WDB coco | 4.98B |
| Solasia Pharma K.K. | 326.00M |